pharmaceutical investing CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
pharmaceutical investing CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection
pharmaceutical investing CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
pharmaceutical investing CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
pharmaceutical investing CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology Annual Meeting
pharmaceutical investing CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
pharmaceutical investing CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
Precious Metals & Critical Minerals Virtual Investor Conference Agenda Announced for July 22nd & 23rd
Metalsource Mining Identifies High Priority Drill Targets Across 2.4 Kilometres to Drive the Next Phase of Exploration at Silver Hill
Skyharbour Signs Letter of Intent with Purecore to Option its Yurchison Uranium Property in the Athabasca Basin
Purecore Signs Letter of Intent with Skyharbour to Option the Yurchison Uranium Property in Athabasca Basin
Finlay Minerals announces the commencement of its 2026 Exploration Programs on its PIL & ATTY Properties
